Elekta AB (publ) (EKTAY) Stock Price & Analysis
Elekta AB (publ) (EKTAY) — price $6.04 (-2.27%), as of the Nov 19, 2026 trading session; market cap $2.31B.
Educational signal · not a buy or sell recommendation · How to read this
Elekta AB (publ) · EKTAY
Elekta AB (publ) is a Swedish medical technology company specializing in clinical solutions for cancer and brain disorders. Their offerings include radiation therapy systems, neurosurgery products, and treatment management software.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.04 | |
| Change on the day | -2.27% | |
| 52-week range | $4.35 – $6.93 | |
| Market capitalisation | $2.31B | — |
| Price / earnings (trailing) | 76.25 | |
| Shares traded on the day | 5.0K |
Price & events
Other perspectives
Council score for Elekta AB (publ) (EKTAY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Elekta AB (publ) (EKTAY), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Elekta AB (publ) (EKTAY) is the company analyzed here. It employs 4,102 people and is led by Jakob Just-Bomholt. In Q1 FY2027 it reported revenue of kr3.54B and net income of kr264M. The market values it at $2.31B.
What do the latest results show for Elekta AB (publ) (EKTAY)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of kr3.54B.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | kr3.54B | kr264M | kr0.69 (diluted) |
| Q4 FY2026 | kr4.77B | -kr868M | -kr2.30 (diluted) |
| Q3 FY2026 | kr4.06B | kr10M | kr0.03 (diluted) |
| Q2 FY2026 | kr4.07B | kr230M | kr0.60 (diluted) |
What are the financial strengths and risks for Elekta AB (publ) (EKTAY)?
Short answer · as of
The distress and quality screens read Altman Z 1.41 · Piotroski F 5. Trailing ratios: ROE -4.7% · ROA -1.4% · current ratio 0.86 · earnings yield -1.5% · free-cash-flow yield 10.5%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.41 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-4.7%) — the business is not currently generating profit on shareholder capital.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held EKTAY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported EKTAY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: EKTAY Stock
These answers are editorial: 1 of these 8 answers is drawn from the EKTAY research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is EKTAY a good stock to buy?
Stock Expert AI does not rate EKTAY buy, sell or hold. Elekta AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the EKTAY stock price today?
The last price recorded for Elekta AB (publ) (EKTAY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about EKTAY stock?
Analyst coverage of EKTAY stock is limited due to its OTC listing and ADR status. However, analysts generally recognize Elekta's established position in the radiation therapy and neurosurgery markets.
What are the key factors to evaluate for EKTAY?
Evaluate EKTAY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Emerging Markets Expansion: Expanding into emerging markets, such as China and India, offers significant growth potential. Not financial advice.
How frequently does EKTAY data refresh on this page?
EKTAY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven EKTAY's recent stock price performance?
Elekta AB (publ) (EKTAY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established market position in radiation therapy and neurosurgery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EKTAY overvalued or undervalued right now?
The trailing P/E of Elekta AB (publ) (EKTAY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research EKTAY before investing?
Before investing in Elekta AB (publ) (EKTAY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com